These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 17644541

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
    Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I.
    Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
    [Abstract] [Full Text] [Related]

  • 7. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
    Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM.
    Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
    [Abstract] [Full Text] [Related]

  • 8. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 9. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.
    Walsh CA, Fearon U, FitzGerald O, Veale DJ, Bresnihan B.
    Clin Exp Rheumatol; 2008 Sep; 26(4):656-8. PubMed ID: 18799100
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A.
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [Abstract] [Full Text] [Related]

  • 12. B cells in rheumatoid arthritis: from hypothesis to the clinic.
    Keystone EC.
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525
    [Abstract] [Full Text] [Related]

  • 13. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
    Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A.
    Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
    [Abstract] [Full Text] [Related]

  • 14. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD.
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [Abstract] [Full Text] [Related]

  • 16. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab.
    Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL.
    Arthritis Res Ther; 2008 Mar; 10(5):R105. PubMed ID: 18761748
    [Abstract] [Full Text] [Related]

  • 17. IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis.
    Navrátilová A, Andrés Cerezo L, Hulejová H, Bečvář V, Tomčík M, Komarc M, Veigl D, Tegzová D, Závada J, Olejárová M, Pavelka K, Vencovský J, Šenolt L.
    Front Immunol; 2021 Mar; 12():745523. PubMed ID: 34745117
    [Abstract] [Full Text] [Related]

  • 18. [Targeting CD20 in rheumatoid arthritis].
    Saito K, Tanaka Y.
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [Abstract] [Full Text] [Related]

  • 19. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM.
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.